Addyi named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards

RALEIGH, N.C. – Sprout Pharmaceuticals today announced that Addyi has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of the most trusted and influential honors a brand can receive. 

The Oprah Daily Menopause O-wards highlight products that meaningfully improve the lives of women in menopause and midlife. Addyi's recognition reflects its status as a treatment doctors trust and choose more than any other for Hypoactive Sexual Desire Disorder (HSDD), backed by a one-of-a-kind approach to treating low desire and robust clinical proof that earned FDA approval for women under age 65.

"This recognition matters because it finally puts sexual health where it belongs—at the center of the conversation on women's health and longevity," said Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals. "For too long, women were told to downplay or dismiss changes in desire. Addyi refuted that narrative with clinical evidence. Being honored by Oprah Daily reinforces what the science shows and what women deserve to hear: HSDD is common, it's treatable, and it warrants real medical attention."

The honor follows a pivotal moment for women's sexual health: in December 2025, the U.S. Food and Drug Administration expanded Addyi's approval from premenopausal women to include women with HSDD under 65 regardless of peri or post-menopausal status. This approval closed a long-standing care gap and recognized Addyi's well-established safety and efficacy profile, backed by more than a decade of clinical and real-world data.

Regarded as a powerful endorsement among consumers, clinicians, and cultural voices, the Oprah Daily Editor's Choice seal reflects a broader shift toward normalizing conversations about menopause, desire, and women's quality of life—topics long overlooked by medicine and media alike.

"Menopause does not end a woman's sexuality but too often, women are made to feel invisible or untreatable when desire changes. I see it every day in my practice," said Dr. Kelly Casperson, board-certified urologist, sexual health specialist, and bestselling author of The Menopause Moment. "When women are offered real treatment options, they get something priceless back: hope. Addyi gives clinicians a science-backed option for HSDD before or after menopause and opens the door to more honest, informed conversations about sexual health at midlife and beyond.'

Since its FDA approval in 2015, Addyi has remained the No. 1 prescribed treatment for HSDD, shaping how women's sexual health is understood and treated across the lifespan. Sprout Pharmaceuticals continues to lead the charge for evidence-based care and long-overdue equity in women's health.